A phase I dose-escalation study of BGB-290, a novel PARP1/2 selective inhibitor in patients with advanced solid tumors

Jason D. Lickliter, Hui Kong Gan, Tarek Meniawy, Jason Yang, Lai Wang, Lusong Luo, Ni Lu, Michael Millward

Research output: Contribution to journalAbstract/Meeting Abstractpeer-review

6 Citations (Web of Science)
Original languageEnglish
Number of pages3
JournalJournal of Clinical Oncology
Issue number15
Publication statusPublished - 20 May 2016
Event52nd Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) - Chicago, United States
Duration: 3 Jun 20167 Jun 2016

Cite this